Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
gptkb:cobimetinib
|
| gptkbp:administrativeDivision |
once daily
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinicalTrials |
Cohort Study
Phase III Open-label Study Phase II Study Phase III Study Randomized Trial |
| gptkbp:discontinued |
2019
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:formulation |
oral tablet
|
| gptkbp:hasPopulation |
adults
patients with BRAF mutation |
| https://www.w3.org/2000/01/rdf-schema#label |
Cotellic
|
| gptkbp:impact |
28 days
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers other cancer medications |
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
biomarkers
combination therapies long-term outcomes resistance mechanisms patient selection adverse effects management |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
not recommended during pregnancy
not recommended while breastfeeding |
| gptkbp:sideEffect |
fatigue
headache nausea fever vomiting decreased appetite diarrhea skin rash liver problems high blood sugar |
| gptkbp:skills |
20 mg
60 mg |
| gptkbp:storage |
room temperature
|
| gptkbp:succeededBy |
improved overall survival
increased progression-free survival |
| gptkbp:triggerType |
MEK_inhibitor
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:variant |
vemurafenib
|